Trending in Longevity

PEARL trial readouts on rapamycin in healthy humans driving major clinical and community buzz in 2026. Top rapalog discussion across all platforms.

GLP-1s now discussed far beyond weight loss—cardiovascular, kidney, liver, and epigenetic aging benefits driving intense 2026 research interest.

First-in-human FDA-cleared trials and OSK factor programs make partial reprogramming the hottest longevity biotech frontier in 2026.

Semaglutide's healthspan benefits beyond obesity—including epigenetic age reduction signals—keep it a top longevity topic in 2026.

Fourth-generation causality-enriched biological age clocks now used as clinical endpoints in trials, driving massive research and consumer interest.

Tirzepatide's dual GIP/GLP-1 mechanism shows superior metabolic and potential healthspan benefits, fueling active longevity research discussions.

TM5614 PAI-1 inhibitor trials showing dramatic biological age reversal claims in short-duration studies, generating outsized buzz in 2026.

OSK and OSKM factor gene therapies advancing toward clinic, including retinal rejuvenation programs, keeping Yamanaka factors front and center.

Senolytic therapies for age-related disease continue strong clinical momentum with multiple trials reporting in 2026.

TM5614 PAI-1 inhibitor generating specific trial buzz after short-course biological age reversal data published in 2026.

Consumer and clinical biological age testing booming as multi-omic panels and epigenetic clocks become accessible longevity endpoints.

mTOR pathway inhibition remains a central longevity mechanism, boosted by PEARL trial data and immune rejuvenation findings in 2026.

NMN and nicotinamide riboside remain top longevity supplements with ongoing human trial data and strong consumer and podcast presence.

OSK reprogramming without c-Myc advancing toward first human trials, including age-related optic neuropathy as lead indication.

Metformin remains a key repurposed longevity drug in TAME trial follow-up discussions and aging-specific prevention stacks in 2026.

Mitochondrial health as a core aging hallmark drives interest in mitophagy enhancers, NAD+, and urolithin A across research and consumer markets.

GLP-1 cardiovascular benefits independent of weight loss confirmed in major 2025-2026 trials, reshaping longevity drug conversations.

D+Q senolytic combination remains the most clinically advanced senolytic regimen with ongoing trials in multiple age-related diseases.

Laromestrocel MSC therapy for skeletal muscle frailty in phase 2/3 trials represents a major mesenchymal stem cell longevity program.

Chronic low-grade inflammation as a driver of aging has spawned a new wave of inflammaging-targeted therapeutics entering trials in 2026.

Urolithin A's mitophagy-enhancing effects confirmed in multiple human trials, making it a top evidence-backed longevity supplement in 2026.

Valter Longo's FMD continues generating clinical trial data on biological age reduction and disease prevention in 2026.

Peptide therapies including BPC-157, TB-500, and epitalon gaining mainstream longevity community traction with growing biohacker adoption.

mTOR modulation-based immune rejuvenation in older adults improving vaccine efficacy is a key clinical focus entering 2026.

Autophagy enhancement via fasting, spermidine, and pharmacological agents remains a core longevity strategy with growing trial evidence.

Targeting the senescence-associated secretory phenotype to reduce inflammaging is an active drug discovery area with multiple 2026 programs.

Plasma exchange and dilution protocols for biological age reduction gaining clinical and biohacker interest following published 2025-2026 data.

Klotho's role in aging, cognition, and kidney protection driving active drug development and strong academic publication momentum in 2026.

Retatrutide triple agonist (GLP-1/GIP/glucagon) showing superior metabolic effects with emerging longevity implications under active discussion.

HBOT protocols for epigenetic age reversal and telomere effects remain prominent in longevity biohacker and clinical discussion in 2026.

Fisetin remains a widely used over-the-counter senolytic with active Mayo Clinic trials and strong community uptake in longevity stacks.

VO2 max as the strongest single predictor of longevity continues dominating exercise science and longevity podcast discourse in 2026.

Senomorphics that suppress SASP without killing senescent cells represent a growing drug class with multiple 2026 pipeline programs.

Spermidine's autophagy-enhancing and cardiovascular benefits supported by growing human trial evidence, popular in longevity supplement stacks.

Thymic rejuvenation via IL-7, growth hormone, and gene therapy approaches gaining momentum as immune aging reversal strategies in 2026.

AKG supplementation gaining attention for TCA cycle support, epigenetic effects, and healthspan data from animal and early human studies.

Clonal hematopoiesis of indeterminate potential emerging as a key cardiovascular and aging risk factor with new therapeutic intervention targets.

Glycine and N-acetylcysteine combination showing GSH restoration and multiple aging reversal signals in Baylor human trials.

Navitoclax BCL-2/BCL-xL inhibitor advancing as a potent pharmaceutical senolytic in combination cancer and aging trials in 2026.

LDN gaining traction in longevity and biohacker communities for neuroinflammation reduction and immune modulation as an off-label aging intervention.

FGF21 analogs for metabolic, liver, and potential aging benefits advancing in pharma pipelines with 2026 readouts driving longevity interest.

Telomerase activation strategies including TA-65 and gene therapy approaches remain active longevity research and consumer interest areas.

Genomic studies of supercentenarians and centenarian families uncovering novel longevity variants beyond APOE and FOXO3 in 2026.